Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 20/20 | 0.75 |
| ▸ | ROS1 | P08922 | 2/20 | 0.69 |
| ▸ | INSR | P06213 | 7/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19027544 | 0.89 | ALK (0.71) | ALKROS1INSR | |
| SCHEMBL19027410 | 0.87 | ALK (0.82) | ALKROS1INSR | |
| SCHEMBL18759950 | 0.86 | ALK (1.00) | ALKINSR | |
| SCHEMBL25566496 | 0.83 | ALK (0.90) | ALKROS1INSR | |
| SCHEMBL18759938 | 0.82 | ALK (1.00) | ALK | |
| SCHEMBL18760009 | 0.82 | ALK (1.00) | ALK | |
| SCHEMBL4098937 | 0.82 | ALK (0.85) | ALKROS1INSR | |
| SCHEMBL19027801 | 0.82 | ALK (0.82) | ALKROS1INSR | |
| SCHEMBL19027798 | 0.81 | ALK (0.74) | ALKROS1INSR | |
| SCHEMBL19027393 | 0.81 | ALK (0.74) | ALKROS1INSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10350210-B2 | EGFR and ALK dual inhibitor | PRECEDO PHARMACEUTICALS CO., LTD (CN) | 2019-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10350210-B2 | EGFR and ALK dual inhibitor | ALK, EGFR, ERBB2 | ALK 1/4885ROS1 31/4885INSR 969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.